CJC No DAC/Ipamorelin is a research blend pairing two growth hormone secretagogues: CJC-1295 without DAC (a modified GHRH 1-29 analog) and Ipamorelin (a selective ghrelin/GHS-receptor agonist). The combination is studied because the two components act on distinct receptor systems, the GHRH receptor and the GHS receptor, allowing researchers to examine convergent signaling in somatotroph-model systems. Puritide Research supplies this blend as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›CJC No DAC/Ipamorelin 5+5 mg Vial
- ›CJC No DAC/Ipamorelin 10+10 mg Vial
Product Specifications
- Application
- Dual growth hormone secretagogue signaling research (GHRH-R / GHS-R)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- CJC-1295 (No DAC): C152H252N44O42; Ipamorelin: C38H49N9O5
- CAS Number
- CJC-1295 (No DAC): 863288-34-0; Ipamorelin: 170851-70-4
- Molecular Weight
- CJC-1295 (No DAC): ~3367.9 g/mol; Ipamorelin: ~711.9 g/mol
- Synonyms
- CJC-1295 No DAC/Ipamorelin blend, Mod GRF (1-29)/Ipamorelin, GHRH analog + GHS peptide stack
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is CJC No DAC/Ipamorelin?
CJC No DAC/Ipamorelin is a co-formulated blend of two research peptides. CJC-1295 without DAC, also called modified GRF (1-29), is a 29-amino-acid analog of growth hormone-releasing hormone (GHRH) carrying substitutions that improve enzymatic stability. Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a).
The two components are studied together because they engage separate receptor systems that both converge on somatotroph cells in the pituitary. In experimental models this pairing is used to investigate how GHRH-receptor and GHS-receptor signaling interact, and how combined stimulation compares with either pathway alone.
Present understanding derives from in vitro assays, animal models, and human research on related compound classes. Findings should be interpreted within their experimental context and not treated as established clinical outcomes. Puritide Research supplies this blend strictly for laboratory use; it is not approved for human or veterinary application.
Puritide Research supplies CJC No DAC/Ipamorelin strictly for laboratory research use. Not for human or veterinary use.
Research Use Only
